Supera-CBD / TNF Pharmaceuticals - LARVOL DELTA

MyMD Announces U.S. Drug Enforcement Administration (DEA) Determines Supera-CBD is not a Controlled Substance or Listed Chemical (Businesswire) - "MyMD Pharmaceuticals, Inc...announced that the U.S. Drug Enforcement Administration (DEA) has conducted a scientific review and determined that investigational cannabinoid Supera-CBD™ is not currently considered a controlled substance or listed chemical. The scientific review of the chemical structure of Supera-CBD was conducted in accordance with the Controlled Substances Act (CSA) and its governing regulations."

Clinical • CNS Disorders • Epilepsy

MyMD Pharmaceuticals Receives Grant From European Patent Office for Supera-CBD Compound (Businesswire) - "MyMD Pharmaceuticals, Inc...announced today that it received a decision to grant from the European Patent Office in its application no. EP 3755318 A1. The allowed claims cover MyMD’s Supera-CBD™ compound as a new molecular entity and pharmaceutical formulations containing the compound."

Patent • CNS Disorders • Epilepsy • Pain

MyMD Pharmaceuticals Announces New Data Demonstrating 8,000 Times Higher Potency of Novel Synthetic Supera-CBD over Plant-Derived CBD (Businesswire) - "MyMD Pharmaceuticals, Inc...announced new data demonstrating Supera-CBD’s superior potency over CBD by factor of 8,000 times. Supera-CBD is MyMD’s pre-clinical patented synthetic cannabidiol (CBD) derivative that is being developed as a pharmaceutical drug to address anxiety, pain, and neurodegeneration...Supera-CBD is currently on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain."

Preclinical • CNS Disorders • Epilepsy

MyMD Pharmaceuticals to Present its Novel Therapeutic Platforms for Extending Healthy Lifespan at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15 (Businesswire) - "MyMD Pharmaceuticals, Inc...will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021...During this presentation, Chris Chapman, M.D., President, Director and Chief Medical Officer, and Adam Kaplin, M.D., PhD, Chief Scientific Officer will discuss the multiple indications for each of MyMD’s novel drug candidates...Supera-CBD is being developed to address anxiety, chronic pain, addiction, and seizures, and is on a path toward human clinical trials as a therapy for epilepsy, followed by chronic pain."

Clinical • CNS Disorders • Epilepsy

Johns Hopkins Medicine Researchers to Present Data on MyMD Pharmaceuticals’ Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit (Businesswire) - "MyMD Pharmaceuticals, Inc...announced today that researchers from the Johns Hopkins University School of Medicine will present the results of new research on the company’s compound Supera-CBD at the 3rd Annual Neuroimmunology Drug Development Summit. The poster presentation will discuss the preclinical cannabidiol (CBD) derivative that targets endogenous cannabinoid receptor type 2 for the treatment of psychiatric disorders. The researchers studied the compound in depression and anxiety-related phenotypes in mice."

Preclinical • CNS Disorders • Depression

MyMD Pharmaceuticals Announces Issuance of Allowance from United States Patent and Trademark Office for Synthetic Cannabinoid Compounds (Businesswire) - "MyMD Pharmaceuticals, Inc....announced today that the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for application no. 16/612,472, entitled 'Synthetic Cannabinoid Compounds for the Treatment of Substance Addiction and Other Disorders'. The allowed claims cover the new molecular entity Supera-CBD as well as pharmaceutical compositions containing the compound....Supera-CBD is a non-toxic, synthetic, preclinical cannabidiol derivative that has been shown in in vitro studies to be approximately 7-8x more effective than plant-derived CBD in inhibiting MAO-A and MAO-B and more than 3x more effective than plant-derived CBD in inhibiting CB2...is on an expected path toward human clinical trials as a proposed therapy for epilepsy, followed by chronic pain."

New molecule • Patent • Preclinical • CNS Disorders • Epilepsy • Pain